Aardvark Therapeutics
Manasi Sinha Jaiman, MD, MPH, currently serves as Chief Medical Officer at Aardvark Therapeutics and Scientific Advisor at Tolerance Bio. Previously, Manasi was Chief Medical Officer at ViaCyte and Vice President of Clinical Development at Vertex Pharmaceuticals, overseeing the integration of ViaCyte following its acquisition. With extensive experience at leading institutions including Massachusetts General Hospital and Covance, Manasi has a strong focus on diabetes and obesity-related research, having contributed to the development of innovative diabetes management systems. Educational credentials include an MD from the Medical University of South Carolina and an MPH from Tulane University School of Public Health and Tropical Medicine, augmented by advanced training at Harvard Medical School.
This person is not in any teams
Aardvark Therapeutics
Aardvark Therapeutics is a clinical stage biopharmaceutical company focused on developing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications.